Abstract
The rising incidence of diabetes, metabolic syndrome, and subsequent vascular diseases is now a major public health problem in industrialized countries. New therapeutic strategies to prevent these diseases are urgently needed worldwide. It is well known that calorie restriction (CR) can retard the aging process in organisms ranging from yeast to rodents, and delay the onset of numerous age-related diseases including diabetes. Molecules that mimic CR metabolically are therefore potentially new therapeutic targets for age-related diseases. Silent information regulator 2 (Sir2) is an important player in CR-mediated life span extension. There is also increasing evidence that one of the seven mammalian sirtuins, SIRT1, is involved in regulating cellular processes such as apoptosis. SIRT1 has also been implicated in glucose homeostasis and lipid metabolism in various tissues including adipose tissues, liver, pancreas, and skeletal muscle. This review summarizes current understanding of the biological functions of SIRT1, and discusses its potential as a pharmacological target for fighting metabolic and vascular diseases.
Keywords: Diabetes, sirtuins, calorie restriction, CR mimetics, vascular complications, SIRT1 activator
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Volume: 10 Issue: 1
Author(s): Shinji Kume, Takashi Uzu, Atsunori Kashiwagi and Daisuke Koya
Affiliation:
Keywords: Diabetes, sirtuins, calorie restriction, CR mimetics, vascular complications, SIRT1 activator
Abstract: The rising incidence of diabetes, metabolic syndrome, and subsequent vascular diseases is now a major public health problem in industrialized countries. New therapeutic strategies to prevent these diseases are urgently needed worldwide. It is well known that calorie restriction (CR) can retard the aging process in organisms ranging from yeast to rodents, and delay the onset of numerous age-related diseases including diabetes. Molecules that mimic CR metabolically are therefore potentially new therapeutic targets for age-related diseases. Silent information regulator 2 (Sir2) is an important player in CR-mediated life span extension. There is also increasing evidence that one of the seven mammalian sirtuins, SIRT1, is involved in regulating cellular processes such as apoptosis. SIRT1 has also been implicated in glucose homeostasis and lipid metabolism in various tissues including adipose tissues, liver, pancreas, and skeletal muscle. This review summarizes current understanding of the biological functions of SIRT1, and discusses its potential as a pharmacological target for fighting metabolic and vascular diseases.
Export Options
About this article
Cite this article as:
Kume Shinji, Uzu Takashi, Kashiwagi Atsunori and Koya Daisuke, SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187153010790827957
DOI https://dx.doi.org/10.2174/187153010790827957 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Progenitor Cells Dysfunction and Senescence: Contribution to Oxidative Stress
Current Cardiology Reviews Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design A Review Article: Sevelamer Hydrochloride and Metabolic Acidosis in Dialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Aspirin Resistance: Detection, Mechanisms and Clinical Implications
Current Cardiology Reviews The Role of Co-Infections in Mother-to-Child Transmission of HIV
Current HIV Research Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Diagnosis of Vulnerable Plaque and Vulnerable Patient by Coronary Angioscopy and Multi-detector Row Computed Tomography (MDCT) — From Invasive to Non-invasive Plaque Imaging
Vascular Disease Prevention (Discontinued) Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders
Current Medicinal Chemistry The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy